Airship Unveils AI Agents to Speed Brands' Delivery of High-Impact Customer Experiences
10.7.2025 15:00:00 CEST | Business Wire | Press Release
Airship, the cross-channel customer experience company, today built on its leadership in no-code native mobile experiences by unveiling Airship AI Agents. These task-specialized, intelligent agents automate the creation, testing and optimization of the entire customer experience — from the orchestration of highly personalized cross-channel messaging to the resulting experiences and outcomes on brands' critical conversion destinations, their apps and websites.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250710496272/en/
Airship AI Agents work independently or in tandem to create, test and optimize cross-channel messages and app and web experiences to achieve specific business goals, closing the loop between testing, learning and action at a speed and scale that was previously impossible.
Unlike generic AI tools, Airship’s agents work in concert, enabling a continuous, goal-based optimization loop. For example, a retail brand can now:
- Instantly create a rich, multi-screen onboarding Story or a branching Survey to capture customer preferences with the Scene AI Agent, driving greater engagement and valuable zero-party data collection for future personalization.
- Use the Experimentation AI Agent to automatically and continuously test which message variant and app or website experience best drives conversion or other goals, optimizing the path from messaging to outcome.
- Close the loop with the Recommendation AI Agent, which delivers prescriptive next-steps that marketing and product teams can implement in just a few clicks to scale performance.
Each agent is designed to work independently or in tandem, allowing teams to start small with the agent that solves their most pressing need and scale over time to unlock powerful agentic benefits. By default, every Airship AI Agent keeps a human in the loop, ensuring teams retain full control and transparency. As the agents learn and adapt to achieve specific goals, brands will be able to adjust their level of autonomous operation—providing a responsible, scalable path to greater efficiency.
“For too long, teams have been stuck in a cycle of manual creation and analysis that prevents them from moving at the speed of their customers. They need a system that not only creates experiences, but continuously optimizes them toward specific goals," said Mike Herrick, CTO, Airship. "Our AI Agents are the natural evolution of our no-code platform, automating the entire creation-to-optimization process that we first enabled teams to accomplish without developer support. Airship AI Agents now close the loop between testing, learning and action at a speed and scale that was previously impossible. By keeping teams in control of this powerful cycle, we are empowering them to connect every marketing effort and customer interaction to meaningful business outcomes."
The task-specialized AI agents are purpose-built to solve critical pain points:
- The Scene AI Agent acts as an instant creator, transforming simple prompts or existing images into a variety of fully-branded, interactive app and web experiences—from onboarding flows and activation sequences to rich Stories and branching Surveys.
- The Experimentation AI Agent serves as a tireless analyst, recommending and running complex multivariate tests on app or web experiences and cross-channel messages to continuously optimize for specific business goals.
- The Recommendation AI Agent functions as a strategist, closing the optimization loop by delivering prescriptive next-best actions that turn complex performance data into clear, easily implemented suggestions.
A fourth agent, the Accessibility AI Agent, serves as a compliance guardian, proactively generating elements to ensure experiences are built to meet accessibility requirements and critical standards like the new EU Accessibility Act that went into effect June 28, mitigating significant legal and financial risk.
This focus on safe and responsible AI is foundational to the entire system. Underpinning all agents is the Airship Brand Hub, which ensures every piece of AI-generated content, from app and web experiences to cross-channel campaign copy uses the brand’s style guide adhering to the company’s unique voice, tone, and visual identity. It solves the core tension between generating content at speed and scale, while maintaining brand integrity.
“Using AI agents to generate contextual insights and action them in a role- and scenario-relevant way will supercharge insights-driven marketing and sales by enabling differentiated interactions based on relevance, responsiveness, and value, not quantity or scale. AI agents must be able to continuously learn about your business and customers using quality first-party data … human oversight is needed now more than ever to help AI agents learn about the business and its customers to best guide and use their goal-oriented behaviors” (Forrester Research, Inc., “AI Agents: What It Means For B2B Marketing, Sales, And Product,” April 1, 2025).
About Airship
Airship is trusted by the world's leading brands such as Alaska Airlines, BBC and The Home Depot to drive revenue growth and customer loyalty with exceptional cross-channel customer experiences.
Airship's no-code, AI-powered platform makes it easy for marketing, product and growth teams to create, test and orchestrate hyper-personalized experiences across apps, websites, email, SMS, mobile wallets and more. Airship's modular network of AI agents empowers teams to continuously enrich customer data and rapidly launch experiments to confidently improve every interaction and the entire end-to-end customer journey, helping brands drive repeatable conversions, higher lifetime value and durable revenue growth.
For more information, visit www.airship.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250710496272/en/
Contacts
Media Contact
North America:
Kali Myrick
Kali Myrick Communications
+1 503-580-4645
kali@kalimyrick.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom